Skip to main content
Premium Trial:

Request an Annual Quote

PathoQuest Garners CE Mark for Blood-Based Pathogen Detection Test

NEW YORK (GenomeWeb) – PathoQuest, an Institut Pasteur spinout, said today that it has received CE marking for iDTECT Blood, a next-generation sequencing-based metagenomics test for blood pathogens.

The "sample-to-report" test is designed to detect bacteria and viruses in blood samples from patients with suspected infections, especially immunocompromised patients, PathoQuest said.

With the CE mark, PathoQuest will now offer the test through an early-access program in selected countries, the company said.

"We believe iDTECT Blood will contribute to improved antibiotic stewardship and precision medicine strategies in infectious diseases, ultimately leading to better patient care" PathoQuest Chief Medical Officer Helene Peyro-Saint-Paul said in a statement.

Olivier Lortholary, professor and chair of the Department of Infectious and Tropical Diseases at Hôpital Necker-Enfants Malades in Paris, noted that in certain clinical situations, especially when a patient is immunocompromised, culture and PCR tests are often unable to provide sufficient information to select the most appropriate targeted anti-infective therapy.

"With the availability of iDTECT Blood, clinicians will be able to expand their experience on the basis of the results already obtained in a proof-of-concept study completed at Necker-Enfants Malades and Européen Georges Pompidou hospitals on a cohort of over 100 immunocompromised patients," Lortholary added.

The Scan

Follow-Up Data Requests to Biobank Participants Ineffective, Study Finds

An effort to recontact biobank enrollees for additional information reports low participation in a new BMJ Open study.

Study Finds Widespread Transmission of Resistant Bacteria in Vietnam Hospitals

A sequencing study in The Lancet Microbe finds widespread transmission of drug-resistant Escherichia coli, Klebsiella pneumoniae, and Acinetobacter baumannii in two Vietnam ICUs.

Novel Brain Cell Organoids Show Promise for Autism Research

University of Utah researchers report in Nature Communications on their development of brain cell organoids to study SHANK3-related autism.

Study Finds Few FDA Post-Market Regulatory Actions Backed by Research, Public Assessments

A Yale University-led team examines in The BMJ safety signals from the US FDA Adverse Event Reporting System and whether they led to regulatory action.